{
  "doc_id": "CT-17321_LENVIMA_PIC_EI_Avis3_CT17321",
  "created_date": "2019",
  "country": "FR",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "C T OMMISSION OF RANSPARENCY 9 October 2019 Date of examination by the Commission: 10 July 2019 A hearing was held on 9 October 2019 on the ommission of the ransparen adopted on 17 July 2019.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "LENVIMA 4 mg hard capsule",
      "text": "Box of 30 capsules (CIP: 34009 300 189 4 1)",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "LENVIMA 10 mg hard capsule",
      "text": "Box of 30 capsules (CIP: 34009 300 189 5 8) EISAI Laboratory",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "ATC code L01XE29 (protein kinase inhibitor)",
      "text": "Reason for examination Extension of indication Social safety (CSS L.162-117) Lists concerned Communities (CSP L.5123-2) \"LENVIMA is indicated as monotherapy for the treatment of patients Subject indication adults with advanced or non-resectable hepatocellular carcinoma (CHC) who have not received previous systemic treatment.\" Defa orable notice to be taken as a harge in India on er e SMR ASMR ISP Place in the therapeutic strategy HAS - Directi a u tion d The Commission considers that the medical service provided by LENVIMA is insufficient in the light of the therapies available to justify treatment by national solidarity in the extension of the indication of the AMM. Not applicable. LENVIMA is not likely to have an additional impact on public health. Taking into account: - the demonstration of the non-inferiority (without demonstration of superiority) of lenvatinib in relation to sorafenib in terms of overall survival and methodological limitations of the",
      "start_page": 1,
      "end_page": 5
    },
    {
      "heading": "8.1.1.1. Method",
      "text": "Study REFLECT-304 (E7080-G000-304) Masatoshi Kudu et al., Lenvatinib versus sorafenib in first-line treatment of patients with Reference unresectable hepatocellular carcinoma: a randomised phase 3 non – inferiority trial. Lancet. 2018;391:1163-1173 Clinicaltrials.gov NCT01761266 Demonstrate non-inferiority in terms of overall survival (SG) of lenvatinib versus sorafenib Primary primary treatment line objective for patients with non-resectable hepatocellular carcinoma Phase III, non-inferiority, multi-centre, international, controlled versus sorafenib, randomized (stratified randomization on geographic area, vein invasion Type of study extrahepatical portal or extent, ECOG status and weight) and conducted in two parallel groups of analysis North America Date of analysis:",
      "start_page": 7,
      "end_page": 10
    },
    {
      "heading": "8.1.1.2. Results",
      "text": "A total of 954 patients were randomized (478 in the lenvatinib group and 476 in the sorafenib group), corresponding to the ITT population. Of these, 3 patients (2 in the lenvatinb group and 1 in the sorafenib group) did not receive treatment. The SAS population for the tolerance analysis was therefore composed of 476 patients in the lenvatinib group and 475 in the sorafenib group. The PP population included 467 patients in the lenvatinb group and 462 in the sorafenib group (11 and 14 major deviations to the protocol). 的 Follow-up and exposure to treatment At the time of analysis (13 November 2016), the median duration of treatment was 5.7 months (max.min: 0-35) in the lenvatinib group and 3.7 months (max.min: 0.1-38.7) in the sorafenib group.",
      "start_page": 10,
      "end_page": 18
    },
    {
      "heading": "8.3.2 Data from PSURs",
      "text": "The safety data for lenvatinib also come from the last periodic pharmacovigilance report (PSUR) covering the period from 13 February 2017 to 12 August 2017. During this period: - 522 cases of pharmacovigilance were recorded, - no new pharmacovigilance signal was recorded, - special monitoring of pharmacovigilance of interstitial pneumonitis, dysphagia, hyponatraemia, dissection of the aorta was performed, - analysis of pharmacovigilance observations showed no new facts likely to alter the SPC of LENVIMA, - prolongation of the QT interval, initially considered a significant potential risk is now classified as a significant risk identified in the PGR and the risk of pancreatitis has been removed.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "\" 4.8 Undesirable effects",
      "text": "Safety Profile Summary The safety profile of lenvatinib is based on the data collected... from 496 patients with CHC, which was used to characterize only common adverse reactions in patients with CHC. CHC The most frequently reported adverse reactions (in ≥ 30% of patients) are hypertension (44.0%), diarrhoea (38.1%), decreased appetite (34.9%), fatigue (30.6%) and weight loss (30.4%). The most significant serious adverse reactions were: hepatic impairment (2.8%), hepatic encephalopathy (4.6%), hemorrhage of oesophageal varicose veins (1.4%), cerebral haemorrhage (0.6%), arterial thromboembolic events (2.0%), including myocardial infarction (0.8%), cerebral infarction (0.4%) and stroke (0.4%), and renal/renal insufficiency (1.4%).\"",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "8.3.4 Data from the RMP",
      "text": "LENVIMA is the subject of a Risk Management Plan (RMP) which was updated as of June 27, 2018 (version 10.6): . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 19,
      "end_page": 22
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)>",
      "text": "Row 1:--Row 2:--Lenvatinib--Row 3:--",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)>",
      "text": "Row 1: ATC Code: L01XE29 (protein kinase inhibitor) Row 2: Reason for Examination: Extension of Indication Row 3: Relevant Lists: Social Safety (CSS L.162-117) Communities (CSP L.5123-2) Row 4: Relevant Indication: \"LENVIMA is indicated as monotherapy for the treatment of adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) who have not received previous systemic treatment.\"",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)>",
      "text": "Row 1 : - Row 2 : - Defa orable view of harnessing in the indi cation on ern e - Row 3 : -",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1: SMR, the Commission considers that the medical service provided by LENVIMA is:: Row::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1 : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1:1:Place in Row 2::Row 3:Therapeutic Strategy",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)> (from previous page, column 1)",
      "text": "Row 1:的 Row 2:的SMR Row 3:的 Row 4:的 Row 5:的ASMR Row 6:的 Row 7:的 Row 8:的ISP Row 9:的 Row 10:的 Row 11:的Place in Row 12:的Row 13 strategy:的Therapeutic Row 14:",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: a Row 12: Row 13: ue Row 14:",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)> (from previous page, column 3)",
      "text": "Row 1:soundingly inadequate to justify taking in Row 3:sounding national solidarity in the extension of the AMM.How Row 4:sounding Row 5:soundingNothing. Row 6:sounding Row 7:soundingLENVIMA is not likely to have an additional impact on Row 8:swelling public health.How Row 9:sounding Row 9:sounding Row 10:sounding the demonstration of non-inferiority (without demonstration of Row 11:sweetness) of lenvatinib in relation to sorafenib in terms of survival:sounding Row 12:swelling and methodological limitations of this demonstration: Row 13:sounding population (Child-Pugh A, ECOG 0 or 1), Row 14:sounding Row 14:sounding open evidence of the carcinoma:sounded Row 13:sounding population (Child-Pugh A, ECOG 0 or 1):sounded Row 14:sounding open evidence of the carcinoma:sound 15sounding:sounding:sounding:sounding:sounding:sounding the patients:sounding:sounding:sounding:sounding agrounds an open evidence of the evidence of the evidence of the evidence of the evidence of the evidence of the evidence",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)> (from previous page, column 3)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1: AMMA: Initial date (centralised procedure): 28/05/2015 Date of extension of indication (subject of this notice): 20/08/2018 MAH commitments: observational study to characterize the safety profile (including liver toxicity) under real-life conditions of use in Europe in patients with CHC, including those with Child-Pugh B, and to collect overall survival data and patient characteristics upon inclusion. Row 2: Conditions for prescribing and delivering/special status: List I Medicinal product subject to hospital prescription Prescription for oncology specialists or physicians with expertise in cancerology Medicinal product requiring special monitoring during treatment Row 3: ATC-Classification Antineoplastics and immunomodulators L01 Antineoplastic agents L01X Other antineoplastic agents L01XE Kinase protein inhibitors L01XE29 lenvatinib",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1: Initial Dose - Weight ≥ 60 kg 12 mg (three 4 mg oral capsules once daily) -Weight < 60 kg 8 mg (two 4 mg oral capsules once daily) -Row 2: Persistent and intolerable Grade 2 or 3a, -Row 3: Adverse reaction, -Modification, -adapted doseb (weight ≥ 60 kg) -adapted doseb (weight < 60 kg) -Row 4: First occurrence, -Stop to resolution at grade 0 or 1 or initial state, -8 mg (two 4 mg capsules) orally once daily -4 mg (one 4 mg capsule) orally once daily -Row 5: Second occurrence (same or new effect) -Stop to resolution at grade 0 or 1 or initial state, -4 mg (one 4 mg capsule) orally once daily -4 mg (one 4 mg capsule) orally every two days -Row 1: Initial dose, -Weight ≥ 60 kg 12 mg (three 4 mg oral capsules once daily) -Weight < 60 kg 8 mg (two 4 mg oral capsules once daily) -Weight < 60 kg 12 mg",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table underheading <ATC Code L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1:------- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "table underheading <8.1.1.1 Method>",
      "text": "Row 1:-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <8.1.1.1 Method>",
      "text": "Row 1:satoshi Kudu et al., Lenvatinib vs. sorafenib in first-line treatment of patients with Wow 3:satocellular carcinoma: a randomised phase 3 non – inferiority trial.- Row 5:sa-Row 6:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:sa-Row:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <8.1.1.1 Method> (from previous page)",
      "text": "Row 1:--- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "table underheading <8.1.1.1 Method> (from previous page, column 1)",
      "text": "Row 1:1:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "table underheading <8.1.1.1 Method> (from previous page, column 2)",
      "text": "Row 1: Row 2: Row 3: ux crit Row 4: ion Row 5: Row 6: Row 7: ux crit Row 8: nclusi Row 9: Row 10: Row 11: ents Row 12: Row 13:",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "table underheading <8.1.1.1 Method> (from previous page, column 3)",
      "text": "Row 1:-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "table underheading <8.1.1.1 Method> (from previous page)",
      "text": "Row 1:1 (lenvatinib vs. sorafenib) and stratified according to: - Geographic region: Asia-Pacific vs. Western regions (EU, United States etc.) - Invasion of the portal and/or extrahepatic vein: yes vs. no - ECOG performance score: PS = 0 vs. PS = 1 - Body weight: < 60 kg vs. ≥ 60 kg Row 2:",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table underheading <8.1.1.1 Method> (from previous page, column 1)",
      "text": "Row 1:1:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table underheading <8.1.1.1 Method> (from previous page, column 2)",
      "text": "Row 1:1 (lenvatinib vs. sorafenib) and stratified according to: - Geographic region: Asia-Pacific vs. Western regions (EU, United States etc.) - Invasion of the portal and/or extrahepatic vein: yes vs. no - ECOG performance score: PS = 0 vs. PS = 1 - Body weight: < 60 kg vs. ≥ 60 kg Row 2:",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table underheading <8.1.1.2 Results>",
      "text": "In the case of non-inferiority on the primary endpoint, secondary endpoints were tested in a manner that was then tested at the same threshold.",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page)",
      "text": "Row 1 : lenvatinib & B Group Sorafenib & B Group Total Row 2 : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1 : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1 : Genre – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1:-Geographic region – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1:-ECOG PS – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1 : Time since diagnosis - month",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1 : Etiology",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1 : — BCLC stade – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1 :! Child-Pugh Score – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1 : -Vacular invasion and/or extra-hepatiq metastases",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1 : Inferior cirrhosis – n (%)*",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1 : -Concentration in alpha-foetoprotein (AFP)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 1)",
      "text": "Row 1 : Prior anti-cancer treatment – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 2)",
      "text": "Row 1: b------ -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page, column 3)",
      "text": "Row 1:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page)",
      "text": "Row 1:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page)",
      "text": "Row 1:-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page)",
      "text": "Row 1:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "table underheading <8.1.1.2 Results> (from previous page)",
      "text": "Row 1:-Lenvatinib Group--Sorafenib Group--Row 2:--EIG leading to death--(n = 476)--(n = 475)--Row 3:--Row 4:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "table underheading <« 4.8 Undesirable effects>",
      "text": "Row 1:--Lenvatinib Group--Sorafenib Group--Row 2: Adverse event of interest--(n = 476)--(n = 475) Row 3:--n (%)--Row 4: Hepatitistoxicity--227 (47.7)--198 (41.7)--Row 5: Hypertension--212 (44.5)--147 (30.9)--Row 6: Hand-foot syndrome--133 (27.9)--249 (52.4)--Row 7: Proteinuria--125 (26.3)--58 (12.2)--Row 8: Hemorrhage---117 (24.6)--76 (16.0)--Row 9: Hypothyroidism---100 (21.00)--12 (2.5)",
      "start_page": 18,
      "end_page": 18
    }
  ]
}